Teodulfo Blaas' MDR-TB diagnosis meant that he had to give up his job as a laborer. But thanks in part to SES, he's now a successful business owner.

View a slideshow of images depicting PIH's work to fight tuberculosis at our sites around the world.

A team of nurses from PIH's partner organization in Peru lend a hand in Haiti.

Watch a slideshow featuring women from PIH projects around the world.

Last year, Geoff Gusoff arrived in Lima, Peru to volunteer with PIH's partner organization Socios En Salud (SES). After returning to the United States, he reflected on his experience.

Almost three decades after the emerging AIDS pandemic became widely recognized, staff and community members at Partners In Health sites around the world celebrated the achievements they and others have made in combating the spread and deadliness of the disease.

In recognition of its success in combating MDR-TB and other global health issues, Socios En Salud (PIH's partner organization in Peru) recently accepted two distinguished awards

PIH's 15th annual Thomas J. White Symposium focused on the theme "Pushing boundaries: past, present, and future." The program featured a panel of HIV patients who shared their stories of being provided with life-saving antiretroviral drugs. Another panel featured activists who have used the PIH model and philosophy of social justice to create their own programs to provide healthcare to the poor and inspire the next generation of social justice activists. View these panels as well as speeches from PIH co-founders Paul Farmer and Ophelia Dahl.

Socios en Salud teaches youth health promoters (promotores juveniles) valuable communications skills to improve family relations; as well as tutoring skills and health information to help other children in their communities.

Extensively drug-resistant tuberculosis (XDR-TB) is curable with intensive and specialized care conclude two recent studies published in the New England Journal of Medicine (NEJM) and The Lancet. Researchers found that fully 60 percent of the patients enrolled in the studies with XDR-TB were successfully treated and cured.